Inhibikase
IKT

Inhibikase (IKT) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$0.11
EPS estimate
−$0.08
EPS surprise
−37.50%
Revenue
$0.00
Reported
Aug 14, 2025

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 14, 2025−$0.08−$0.11−37.50%$0.00SEC
Q1 2025May 14, 2025−$0.10−$0.15−50.00%$0.00SEC
Q4 2024Mar 27, 2025−$0.09$0.88+1114.99%$0.00SEC
Q3 2024Nov 14, 2024−$0.48−$0.65−35.42%$0.00SEC
Q2 2024Aug 14, 2024−$0.67−$0.66+1.49%$0.00SEC
Q1 2024May 15, 2024−$0.79−$0.73+7.59%$0.00SEC
Q4 2023Mar 27, 2024−$0.85−$0.64+24.71%$501.00SEC
Q3 2023Nov 14, 2023−$1.12−$0.86+23.21%$79,569.00SEC
Q2 2023Aug 14, 2023−$0.92−$1.11−20.65%$116,410.00SEC
Q1 2023May 15, 2023−$0.87−$0.96−10.34%$64,521.00SEC
Q4 2022Mar 31, 2023−$1.14−$1.08+5.26%$53,440.00SEC
Q3 2022Nov 14, 2022−$1.08−$1.08+0.00%$7,291.00SEC
Q2 2022Aug 12, 2022−$1.14−$1.08+5.26%$6,552.00
Q1 2022May 16, 2022−$1.02−$1.08−5.88%$46,031.00
Q4 2021Mar 31, 2022−$1.02−$1.14−11.76%$0.00
Q3 2021Nov 15, 2021−$0.84−$1.08−28.57%$328,459.00

Quarterly revenue

Q3 2021
$328,459.00
Q4 2021
$0.00
Q1 2022
$46,031.00
Q2 2022
$6,552.00
Q3 2022
$7,291.00
Q4 2022
$53,440.00
Q1 2023
$64,521.00
Q2 2023
$116,410.00
Q3 2023
$79,569.00
Q4 2023
$501.00
Q1 2024
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00

Frequently asked questions

  • When did Inhibikase (IKT) last report earnings?

    Inhibikase last reported on Aug 14, 2025, covering fiscal Q2 2025.

  • Did IKT beat earnings estimates?

    No. Inhibikase reported EPS of −$0.11 for Q2 2025 against a −$0.08 estimate — a 37.50% miss.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.